Krystal Biotech, Inc. Expense Breakdown
No Expense Breakdown for KRYS on this site yet.
- 2026-06-30: Reportable $11.31M.
- 2025-06-30: Reportable $8.44M.
Source checked: the stored Expense Breakdown page for KRYS.
Expenses by product
Income Tax Expense (Benefit): each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $11.31M |
| 2025-06-30 | $8.44M |
Research and development: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $14.52M |
| 2025-06-30 | $14.41M |
Selling, General and Administrative Expense: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $39.85M |
| 2025-06-30 | $35.07M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |